[go: up one dir, main page]

SK13492002A3 - Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie - Google Patents

Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie Download PDF

Info

Publication number
SK13492002A3
SK13492002A3 SK1349-2002A SK13492002A SK13492002A3 SK 13492002 A3 SK13492002 A3 SK 13492002A3 SK 13492002 A SK13492002 A SK 13492002A SK 13492002 A3 SK13492002 A3 SK 13492002A3
Authority
SK
Slovakia
Prior art keywords
lps
coli
lipoid
dsm
lipopolysaccharides
Prior art date
Application number
SK1349-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Hans Proppert
Jrgen Malinka
J�Rgen Schulze
Ulrich Sonnenborn
Ulrich Z�Hringer
Artur Ulmer
Ernst Theodor Rietschel
Original Assignee
Pharma-Zentrale Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma-Zentrale Gmbh filed Critical Pharma-Zentrale Gmbh
Publication of SK13492002A3 publication Critical patent/SK13492002A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1349-2002A 2000-03-20 2001-03-20 Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie SK13492002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10013539A DE10013539B4 (de) 2000-03-20 2000-03-20 Lipopolysaccharide aus Escherichia coli, Verfahren zu deren Herstellung und deren Verwendungen
PCT/EP2001/003153 WO2001070756A2 (de) 2000-03-20 2001-03-20 Lipopolysaccharide aus escherichia coli

Publications (1)

Publication Number Publication Date
SK13492002A3 true SK13492002A3 (sk) 2003-03-04

Family

ID=7635468

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1349-2002A SK13492002A3 (sk) 2000-03-20 2001-03-20 Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie

Country Status (28)

Country Link
US (1) US6833451B2 (et)
EP (1) EP1266023A2 (et)
JP (1) JP2003528175A (et)
KR (1) KR20030047878A (et)
CN (1) CN1436245A (et)
AP (1) AP2002002622A0 (et)
AU (2) AU2001273899B2 (et)
BG (1) BG107115A (et)
BR (1) BR0109392A (et)
CA (1) CA2402544A1 (et)
CZ (1) CZ20023469A3 (et)
DE (1) DE10013539B4 (et)
EA (1) EA005217B1 (et)
EE (1) EE200200537A (et)
HK (1) HK1053148A1 (et)
HR (1) HRP20020682A2 (et)
HU (1) HUP0204540A3 (et)
IL (1) IL151785A0 (et)
IS (1) IS6517A (et)
MX (1) MXPA02009215A (et)
NO (1) NO20024480L (et)
NZ (1) NZ520968A (et)
PL (1) PL368447A1 (et)
SK (1) SK13492002A3 (et)
UA (1) UA75068C2 (et)
WO (1) WO2001070756A2 (et)
YU (1) YU71202A (et)
ZA (1) ZA200207408B (et)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
DE10328669B4 (de) * 2003-06-26 2005-12-01 Pharma-Zentrale Gmbh Plasmidfreier Klon des E. coli Stammes DSM 6601
WO2005051321A2 (en) * 2003-11-25 2005-06-09 Washington University Treatment of inflammatory bowel disease through induction of indoleamine 2,3-dioxygenase
US20050238651A1 (en) * 2003-11-25 2005-10-27 Gurtner Gregory J Treatment of inflammatory bowel disease
WO2006025995A2 (en) * 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions and methods using md-2 mutants and chimeric proteins
CN100354428C (zh) * 2005-01-13 2007-12-12 丁友玲 隧道式干热灭菌设备测试用内毒素指示剂的制备方法
EP1961823B1 (en) 2005-11-28 2024-06-12 Biomedical Research Group Inc. Method for producing lipopolysaccharide and lipopolysaccharide
US9664677B2 (en) 2010-04-19 2017-05-30 Massachusetts Institute Of Technology Polymer-nanostructure composition for selective molecular recognition
US20130066064A1 (en) * 2010-05-20 2013-03-14 Glaxosmithkline Biologicals S.A, Novel process
CN105137073A (zh) * 2015-08-06 2015-12-09 中国兽医药品监察所 牛布鲁氏菌胶体金抗体检测试纸条
PL432842A1 (pl) * 2020-02-10 2021-08-16 Uniwersytet Warszawski LPS do zastosowania w indukowaniu u osobnika tolerancji na alergeny pokarmowe wywołujące alergie pokarmowe zależne od IgE
AU2021235152B2 (en) * 2020-03-13 2026-02-05 Hephaistos-Pharma Detoxified lipopolysaccharides (IPS), naturally non-toxic lps, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19844191A1 (de) * 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli

Also Published As

Publication number Publication date
BG107115A (bg) 2003-05-30
ZA200207408B (en) 2003-01-02
EA005217B1 (ru) 2004-12-30
CA2402544A1 (en) 2002-09-10
AP2002002622A0 (en) 2002-09-30
HUP0204540A3 (en) 2003-12-29
CZ20023469A3 (cs) 2003-04-16
NO20024480L (no) 2002-11-20
WO2001070756A3 (de) 2002-05-02
HK1053148A1 (zh) 2003-10-10
HRP20020682A2 (en) 2004-12-31
US6833451B2 (en) 2004-12-21
EE200200537A (et) 2004-04-15
NZ520968A (en) 2005-07-29
NO20024480D0 (no) 2002-09-19
AU7389901A (en) 2001-10-03
HUP0204540A2 (hu) 2003-04-28
US20030108573A1 (en) 2003-06-12
JP2003528175A (ja) 2003-09-24
MXPA02009215A (es) 2004-09-10
YU71202A (sh) 2006-01-16
DE10013539A1 (de) 2001-10-18
WO2001070756A2 (de) 2001-09-27
KR20030047878A (ko) 2003-06-18
AU2001273899B2 (en) 2005-10-06
EA200200997A1 (ru) 2003-04-24
EP1266023A2 (de) 2002-12-18
PL368447A1 (en) 2005-03-21
CN1436245A (zh) 2003-08-13
UA75068C2 (en) 2006-03-15
DE10013539B4 (de) 2006-07-13
BR0109392A (pt) 2003-06-03
IL151785A0 (en) 2003-04-10
IS6517A (is) 2002-08-21

Similar Documents

Publication Publication Date Title
Kulshin et al. Structural characterization of the lipid A component of Pseudomonas aeruginosa wild‐type and rough mutant lipopolysaccharides
Zaehringer et al. Molecular structure of lipid A, the endotoxic center of bacterial lipopolysaccharides
Sabesan et al. Combined chemical and enzymatic synthesis of sialyloligosaccharides and characterization by 500-MHz and proton and carbon-13 NMR spectroscopy
Haishima et al. Structural investigation on the lipopolysaccharide of Escherichia coli rough mutant F653 representing the R3 core type
SK13492002A3 (sk) Lipopolylsacharidy z E. coli, spôsob ich získania a ich použitie
Isshiki et al. Isolation and characterisation of disodium (4-amino-4-deoxy-β-l-arabinopyranosyl)-(1⃗8)-(d-glycero-α-d-talo-oct-2-ulopyranosylonate)-(2⃗4)-(methyl 3-deoxy-d-manno-oct-2-ulopyranosid) onate from the lipopolysaccharide of Burkholderia cepacia
KNIREL et al. Somatic antigens of Pseudomonas aeruginosa: The structure of the O‐specific polysaccharide chain of the lipopolysaccharide from P aeruginosa O13 (Lányi)
Masoud et al. General strategy for structural analysis of the oligosaccharide region of lipooligosaccharides. Structure of the oligosaccharide component of Pseudomonas aeruginosa IATS serotype 06 mutant R5 rough-type lipopolysaccharide
Rau et al. Production and structural analysis of the polysaccharide secreted by Trametes (Coriolus) versicolor ATCC 200801
Holst et al. Chemical structure of the lipid A of Escherichia coli J‐5
JPH06145189A (ja) スフィンゴ糖脂質
JPWO1992012986A1 (ja) スフィンゴ糖脂質
Molinaro et al. Full structural characterization of Shigella flexneri M90T serotype 5 wild-type R-LPS and its Δ galU mutant: glycine residue location in the inner core of the lipopolysaccharide
Rybka et al. Determination of endotoxin by the measurement of the acetylated methyl glycoside derivative of Kdo with gas–liquid chromatography-mass spectrometry
Janusch et al. Structural and biological characterization of highly purified hepta-acyl lipid A present in the lipopolysaccharide of the Salmonella enterica sv. Minnesota Re deep rough mutant strain R595
Cox et al. Structural analysis of the lipopolysaccharide from Vibrio cholerae serotype O22
Ieranò et al. Against the rules: A marine bacterium, Loktanella rosea, possesses a unique lipopolysaccharide
EP0704536B1 (de) Verfahren zur Isolierung und Reinigung von nukleotidaktivierten Zuckern aus biologischen Quellen
Zdorovenko et al. Composition, structure, and biological properties of lipopolysaccharides from different strains of Pseudomonas syringae pv. atrofaciens
Katzenellenbogen et al. 3-Deoxy-octulosonic acid-containing trisaccharide fragment of an unusual core type of some Hafnia alvei lipopolysaccharides
Cescutti et al. The structure of the acidic exopolysaccharide produced by Pseudomonas “gingeri” strain Pf9
Kokoulin et al. Partial structure and immunological properties of lipopolysaccharide from marine-derived Pseudomonas stutzeri KMM 226
CN119372085B (zh) 一种戊糖片球菌、改性胞外多糖及其制备方法和在抗氧化剂制备中的应用
Veremeichenko et al. Specific structural features and immunomodulatory properties of the lipopolysaccharides of Pseudomonas bacteria
Kobatake et al. Lipopolysaccharide isolated from Mycobacterium tuberculosis strain Aoyama B